Business & regional news

Month Year

Email alerts

Sep 18, 2022

MEDTRONIC UNVEILS NEW DATA FROM INVESTIGATIONAL INTREPID™ TRANSCATHETER MITRAL VALVE REPLACEMENT PROGRAM TO EXPAND TREATMENT OPTIONS FOR SEVERE MITRAL REGURGITATION

TCT 2022: Late-breaking data from Intrepid™ Pilot Study 3-year follow-up & 1-year follow-up from Transfemoral EFS study demonstrate promising valve performance Medtronic today announced new data...
- Structural Heart and Aortic
Sep 16, 2022

FIRST-EVER COMPARISON OF MICROCT AND HISTOLOGY IN SELF-EXPANDING TRANSCATHETER AORTIC VALVE REPLACEMENT PATIENTS WITH HYPO-ATTENUATED LEAFLET THICKENING

TCT 2022: Pathological Findings Confirm Importance of Early Detection and Treatment of Thrombus on Valve Leaflets Medtronic today announced findings from its Pathological Study of Hypo-Attenuated...
- Structural Heart and Aortic
Sep 16, 2022

MEDTRONIC ANNOUNCES FULL MARKET LAUNCH IN U.S. OF EVOLUT™ FX NEXT-GEN TAVR SYSTEM FOR TREATMENT OF SYMPTOMATIC SEVERE AORTIC STENOSIS

TCT 2022: Medtronic Unveils Latest Transcatheter Aortic Valve Replacement Data in Late-Breaking Clinical Science and Presentations
- Structural Heart and Aortic
May 17, 2022

Optimized procedure and care pathway with Medtronic Evolut™ TAVR System demonstrates excellent valve performance and procedural outcomes

Mid-term results of Optimize PRO clinical study reinforces benefits of predictability and control using cusp overlap technique
- Structural Heart and Aortic
May 2, 2022

Medtronic announces first enrollment in pivotal trial of patients with moderate, symptomatic aortic stenosis

EXPAND TAVR II Pivotal Trial evaluating the Evolut™ TAVR platform in a new patient population
- Structural Heart and Aortic

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa